NCCN Guidelines Update Strengthens clonoSEQ in Myeloma MRD Testing

What happened

The National Comprehensive Cancer Network (NCCN) has updated its guidelines for multiple myeloma, establishing a dedicated framework for routine minimal residual disease (MRD) assessment and specifically referencing Adaptive Biotechnologies' clonoSEQ as an FDA-cleared assay with 10^-6 sensitivity now preferred. This update reinforces clonoSEQ's position as the only NGS-based MRD assay with broad U.S. reimbursement and sensitivity to one in a million cancer cells, aligning with the company's strategic focus on hematologic MRD. The DeepValue master report maintains a BUY stance, citing Adaptive's defensible leadership in hematologic MRD, anchored by FDA authorizations, Medicare pricing ($2,007/test CLFS; $8,029 MolDX episode), and expanded coverage, along with a large underpenetrated TAM of ~$5.5B. Management targets MRD profitability in 2025, with reduced cash burn guidance and $222M in cash/securities as of Q2'25, providing runway to scale volumes as the guidelines drive adoption. Risks include potential policy shifts in LDT oversight/reimbursement and competition, but the guideline endorsement is a positive inflection that supports the investment thesis.

Implication

Investors should view this NCCN update as an incremental positive that could accelerate clonoSEQ test volumes and ASP expansion, particularly as 10^-6 sensitivity becomes the preferred standard. The specific reference to clonoSEQ as an FDA-cleared assay may further entrench its reimbursement moat and differentiate it from competitors like flow cytometry and emerging ctDNA approaches. The master report's monitoring dashboard emphasizes clonoSEQ volumes and ASP, MRD profitability, and payer policy; this guideline update supports these metrics in the near term. Long-term, the update bolsters the case for clonoSEQ's dominance in hematologic MRD, but investors should remain vigilant about LDT regulation and reimbursement reversals. Overall, the thesis remains BUY with no material shift, but the news raises confidence in the MRD growth trajectory.

Thesis delta

The updated NCCN guidelines provide a positive signal that strengthens the existing BUY thesis. No shift in stance is warranted; the news reinforces clonoSEQ's moat and growth potential, aligning with the master report's view. We maintain BUY with heightened conviction on near-term MRD adoption.